Genentech Study - FVF2428g - A Phase I/II,
Single-Masked, Multicenter Study of the Safety, Tolerability,
and Efficacy of Multiple-Dose Intravitreal Injections of
rhuFab V2 in Combination with Verteporfin (Visudyne TM)
Photodynamic Therapy in Subjects with Neovascular Age-Related
Macular Degeneration
MARINA FVF2598g - A Phase III, Multicenter,
Randomized, Double Masked, Sham Injection-Controlled Study of
the Safety and Efficacy of rhuFab V2 in Subjects with
Neovascular Age-Related Macular Degeneration who Have
Minimally Classic or Occult Lesion
Genetech Study – FVF3192g – A Phase III,
Multicenter, Randomized, Double-Masked, Sham
Injection-Controlled Study of the Efficacy and Safety of
Ranibizumab in Subjects with Subfoveal Choroidal
Neovascularization (CNV) with or without Classic CNV Secondary
to Age-Related Macular Degeneration.
HORIZON FVF3426g - An open-label, multicenter
Extension study to evaluate the safety and tolerability of
RANIBIZUMAB in subjects with subfoveal choroidal
neovascularization (CNV) secondary to age-related macular
degeneration (AMD) who have completed the treatment phase of a
genentech-sponsored RANIBIZUMAB STUDY
CARE ACU-201 - A Phase II, Randomized,
Double-Masked, Controlled, Dose Comparison Study of Cand5 for
Intravitreal Injection for the Treatment of Subfoveal
Choroidal Neovascularization Associated with Wet Age-Related
Macular Degeneration
SAILOR FVF3689g - A Phase IIIb, Single-Masked,
Multicenter, Randomized Study to Evaluate the Safety and
Tolerability of Ranibizumab in Naïve and Previously Treated
Subjects with Choroidal Neovascularization (CNV) Secondary to
Age-Related Macular Degeneration (AMD)
